WO2002009725A1 - Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases - Google Patents
Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases Download PDFInfo
- Publication number
- WO2002009725A1 WO2002009725A1 PCT/US2000/021046 US0021046W WO0209725A1 WO 2002009725 A1 WO2002009725 A1 WO 2002009725A1 US 0021046 W US0021046 W US 0021046W WO 0209725 A1 WO0209725 A1 WO 0209725A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cis
- trans
- composition
- acid
- conjugated linoleic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 47
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 29
- 230000002265 prevention Effects 0.000 title description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 64
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 38
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 38
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 38
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 31
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 31
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 31
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 31
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229960002442 glucosamine Drugs 0.000 claims abstract description 31
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 claims description 12
- IOCYQQQCJYMWDT-UHFFFAOYSA-N (3-ethyl-2-methoxyquinolin-6-yl)-(4-methoxycyclohexyl)methanone Chemical compound C=1C=C2N=C(OC)C(CC)=CC2=CC=1C(=O)C1CCC(OC)CC1 IOCYQQQCJYMWDT-UHFFFAOYSA-N 0.000 claims description 12
- 239000002243 precursor Substances 0.000 claims description 5
- 239000008122 artificial sweetener Substances 0.000 claims description 4
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 abstract description 8
- 235000015872 dietary supplement Nutrition 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000820 nonprescription drug Substances 0.000 abstract description 3
- 230000003467 diminishing effect Effects 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 description 11
- 210000000845 cartilage Anatomy 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001925 catabolic effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 208000012659 Joint disease Diseases 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000003035 hyaline cartilage Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000037231 joint health Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940086763 ascorbic acid 100 mg Drugs 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- VNWKTOKETHGBQD-YPZZEJLDSA-N carbane Chemical compound [10CH4] VNWKTOKETHGBQD-YPZZEJLDSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000008367 cartilage synthesis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000005900 regulation of collagen biosynthetic process Effects 0.000 description 1
- 230000005530 regulation of mRNA processing Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates generally to methods of treatment and products for treating disorders. More specifically, the present invention relates to methods and compositions for preventing, treating or providing relief from inflammation of the joints, osteoarthritis, and other degenerative joint diseases, or from pain associated with these conditions.
- osteoarthritis osteoarthrosis
- osteoarthritis is a degenerative process that is a major cause of invalidism in the adult population.
- Osteoarthritis is the most common form of all articular disorders, and first appears asymptomatically in the second or third decades and becomes almost universal by age 70. Almost all persons by the age of 40 have some pathological changes in weight bearing joints, although relatively few people are symptomatic. See Merck Manual, 16 th Edition, page 1339.
- osteoarthritis The etiology of osteoarthritis is unknown. It appears to be the result of a complex system of interacting mechanical, biological, biochemical, and enzymatic feedback loops. When one or more of these systems fails, the clinical events follow. Many mechanisms can initiate the cellular and tissue events that constitute a final common pathway. Such mechanisms include: congenital joint abnormalities; genetic defects; infectious, metabolic, endocrine, and neuropathic diseases; virtually any disease process that alters the normal structure and function of hyaline cartilage; and acute or chrome trauma to the hyaline cartilage or tissue surrounding same. Merck Manual, id. Analgesics and anti-inflammatory agents are used to attempt to manage this disorder.
- compositions for preventing and treating degenerative joint diseases including osteoarthritis as well as inflammation of the joints, as well as associated pain are provided.
- the formulation includes glucosamine, conjugated linoleic acid, and ascorbic acid. Methods of treatment are also provided.
- the compositions and methods can be provided as an over-the-counter drug, a nutritional supplement, or a prescription medication or component thereof, or as a component of functional or medical foods.
- the present invention provides a method for preventing or treating degenerative joint disease comprising the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid, glucosamine, and ascorbic acid.
- a composition comprising conjugated linoleic acid, glucosamine, and ascorbic acid.
- approximately 0.5 to about 10.0 grams per day of conjugated linoleic acid are administered.
- approximately 500 mg to about 2500 mg per day of glucosamine is administered. Preferably 1500 mg to 2500 mg per day.
- the conjugated linoleic acid is either a pure isomer of octadecadienoic acid, or a mixture of octadecadienoic acid isomers selected from the group consisting of: cis-8, cis-10; cis-8, trans- 10; trans-8, cis 10; trans-8, trans- 10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-9, trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; metabolites thereof, including but not limited to 18:3 cis-6, c
- the composition includes a flavor. In an embodiment, the composition includes an artificial sweetener. In an embodiment, the composition is in pill form. In an embodiment, the degenerative joint disease is osteoarthritis.
- the degenerative joint disease is rheumatoid arthritis, or associated disorders.
- composition comprising a therapeutically effective amount of conjugated linoleic acid, glucosamine, and ascorbic acid.
- the composition comprises approximately 14 % to about 87 % by weight conjugated linoleic acid.
- the composition comprises approximately 12 % to about 82 % by weight glucosamine. In an embodiment, the composition comprises approximately 0.1 % to about 20 % by weight ascorbic acid.
- a method of treating inflammation of the joints comprising the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid, glucosamine, and ascorbic acid. It is an advantage of the present invention to provide a composition for treating inflammation of the joints.
- Another advantage of the present invention is to provide a composition and method for treating osteoarthritis and other degenerative joint diseases. Still further, an advantage of the present invention is to provide a product that can reduce the damaging degenerative process involved in joint disease.
- an advantage of the present invention is to provide a product and method that can reverse the damaging degenerative process involved in joint disease. Moreover, an advantage of the present invention is to provide a composition and method for reducing the debilitating pain associated with joint disease.
- an advantage of the present invention is to provide a composition and method for increasing mobility in patients with degenerative joint disease.
- a further advantage of the present invention is to provide a composition and method for alleviating the chronic catabolic stress response associated with degenerative joint disease.
- an advantage of the present invention is to provide a composition and method for reducing inflammatory response associated with joint discomfort.
- an advantage of the present invention is to provide a composition and method for enhancing cartilage synthesis and/or preventing or minimizing cartilage degradation, thus promoting cartilage repair mechanisms.
- compositions for treating degenerative joint diseases including osteoarthritis as well as inflammation of the joints are provided.
- the formulation includes glucosamine, conjugated linoleic acid, and ascorbic acid. Methods of treatment are also provided.
- the composition and method can be provided as an over-the-counter drug, a nutritional supplement, or a prescription medication.
- Glucosamine is a component of all human tissue and is found in especially high concentrations in the cartilage. Chemically an aminomonosaccharide, glucosamine provides the building blocks for the O-linked and N-linked glycosaminoglycans comprising the matrix of the connective tissues in the body. The sulfate form is readily absorbed from the small intestine - over 90%. Of the absorbed glucosamine, 25% will be excreted in the urine, 65% excreted as exhaled carbon dioxide, and 10% remaining in the tissues. Once it is taken up into the chondrocytes of cartilage, glucosamine is incorporated into proteoglycans. There have been no reports of significant drug interactions of glucosamine with antibiotics or antidepressants.
- Vitamin C is an essential vitamin with an RDI of 60 mg per day.
- the deficiency of this vitamin is associated with poor wound healing, most likely due to poor collagen synthesis.
- This water-soluble vitamin is not usually stored, thus, there is little evidence of toxicity.
- pro-inflammatory cytokines are responsible for the catabolic process occurring in the pathological tissues.
- these pro-inflammatory mediators particularly interleukins (IL-1, IL-6), and tumor necrosis factor (TNF)- ⁇ , are major catabolic compounds involved in the destruction of joint tissues.
- COX-2 cyclooxygenase-2
- PGE 2 prostaglandin
- Conjugated linoleic acid refers to a group of di- and tri-enoic derivatives of linoleic acid that occur naturally in milk and meat of ruminating animals. It can be synthesized in the laboratory and is available commercially as a dietary supplement and has been shown to be nontoxic. Pursuant to the present invention, conjugated linoleic acid can be conjugated linoleic acid such as that set forth in U.S. Patent No. 5,986,116 the disclosure of which is incorporated herein by reference.
- Conjugated linoleic acid appears to modulate the immune system under conditions where COX-2 enzyme is induced by suppressing PGE-2 production.
- the mechanism for the observed anti-inflammatory effects of conjugated linoleic acid in various animal models has been associated with reduced arachidonic acid, a precursor for PGE 2 , accumulation in cell membranes. Any effect conjugated linoleic acid has on the synthesis of eicosanoids should correlate with the uptake of conjugated linoleic acid into neutral phospholipids by cells.
- Conjugated linoleic acid can be readily incorporated in a dose-dependent manner into the tissues of animals consuming diets containing conjugated linoleic acid and a concomitant reduction of arachidonic acid.
- Human articular cartilage is highly specialized tissue, composed of chondrocytes embedded in an extracellular matrix.
- the matrix contains fibrillar components consisting mainly of collagen proteins, and non-fibrillar components, made up of proteoglycans, hyaluronic acid and water.
- Proteoglycan subunits consist of glycosaminoglycans (chondroitin and keratin sulfates) surrounding a protein core.
- Cartilage metabolism involves processes of synthesis, repair and degradation, which are ongoing and mediated by chondrocytes. When the balance among these processes is upset as in ostoarthritis and rheumatoid arthritis, cartilage damage results.
- CLA may inhibit catabolic response while oral glucosamine stimulates the manufacture of substances necessary for proper joint function and stimulate j oint repair.
- Orally administered glucosamine sulfate is selectively taken up by the articular cartilage and stimulates the manufacture of glycosaminoglycan, a key structural component of cartilage. It also promotes the incorporation of sulfur into cartilage. Ascorbic acid acts as a reductive cofactor for post-translational hydroxylation of peptide bound proline and lysine residues during formation of collagen. These hydroxylated arnino acids allow cross-linking which stabilizes the triple helical structure of tropocollagen, an essential subunit of procollagen.
- Ascorbic acid may be involved in gene regulation of collagen synthesis and mRNA processing, hi addition, ascorbic acid influences cellular procollagen secretion and biosynthesis of other connective tissue components such as elastin, proteoglycans and bone matrix. Ascorbic acid is also involved with various immune-related functions such as neutrophil chemotaxis, lymphocyte proliferation, antimicrobial and natural killer cell activities and may also modulate prostacyclin, prostaglandins, and B- and T-cell cyclic nucleotides. The mechanisms for these effects are not clearly resolved, nor the absolute amount of ascorbic acid needed to assist in these areas.
- the product will comprise as active ingredients: approximately 14 % to about 87 % by weight conjugated linoleic acid; approximately 12 % to about 82 % by weight glucosamine SO 4 ; and approximately 0.5 % to about 20 % by weight ascorbic acid.
- the product will comprise as active ingredients: conjugated linoleic acid 45% glucosamine SO 4 45% ascorbic acid 10%
- a dose of the product will comprise two tablets of conjugated linoleic aci ⁇ Vglucosamine sulfate/ascorbic acid.
- Each dose (two tablets) will contain: conjugated linoleic acid powder 500 mg; glucosamine SO 4 500 mg; and ascorbic acid 100 mg.
- the tablets may include the following excipients and flavorings: magnesium stearate, silicone dioxide, croscarmelose sodium, stearic acid, microcrystalline cellulose, calcium phosphate, aqueous base film coat.
- a daily administration of formulation will be given in an amount to provide:
- Contemplative Example No. 2 To treat rheumatoid arthritis, a daily administration of formulation will be given in an amount to provide: 20 mg/kg/day conjugated linoleic acid to 100 mg/kg/day conjugated linoleic acid, 1500 mg/day glucosamine to 2500 mg/day glucosamine, and 100 mg/day ascorbic acid to 400 mg/day ascorbic acid .
- a daily administration of formulation will be given in an amount to provide:
- Contemplative Example No. 4 Prophylactic (maintain joint health) To maintain joint health a daily administration of formulation will be given in an amount to provide: 20 mg/kg/day conjugated linoleic acid to 60 mg/kg/day conjugated linoleic acid, 1500 mg/day glucosamine to 2500 mg/day glucosamine, and 100 mg/day ascorbic acid to 400 mg/day ascorbic acid.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/021046 WO2002009725A1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases |
US10/333,295 US6838451B1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases |
AU2000265107A AU2000265107A1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/021046 WO2002009725A1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002009725A1 true WO2002009725A1 (en) | 2002-02-07 |
Family
ID=21741651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/021046 WO2002009725A1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2000265107A1 (en) |
WO (1) | WO2002009725A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6809115B2 (en) | 2000-09-21 | 2004-10-26 | Nutrition 21, Inc. | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
EP2381940A2 (en) * | 2008-11-26 | 2011-11-02 | Board of Regents, The University of Texas System | A new family of pain producing substances and methods to produce novel analgesic drugs |
US9592301B2 (en) | 2012-09-17 | 2017-03-14 | Board Of Regents Of The University Of Texas System | Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof |
CN116179488A (en) * | 2023-03-09 | 2023-05-30 | 广东唯泰生物科技有限公司 | In vitro amplification method of peripheral blood natural killer cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5603959A (en) * | 1994-03-01 | 1997-02-18 | Scotia Holdings Plc | Fatty acid derivatives |
-
2000
- 2000-08-02 AU AU2000265107A patent/AU2000265107A1/en not_active Abandoned
- 2000-08-02 WO PCT/US2000/021046 patent/WO2002009725A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5603959A (en) * | 1994-03-01 | 1997-02-18 | Scotia Holdings Plc | Fatty acid derivatives |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6809115B2 (en) | 2000-09-21 | 2004-10-26 | Nutrition 21, Inc. | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
EP2381940A2 (en) * | 2008-11-26 | 2011-11-02 | Board of Regents, The University of Texas System | A new family of pain producing substances and methods to produce novel analgesic drugs |
EP2381940A4 (en) * | 2008-11-26 | 2012-12-05 | Univ Texas | A new family of pain producing substances and methods to produce novel analgesic drugs |
US8709391B2 (en) | 2008-11-26 | 2014-04-29 | Board Of Regents Of The University Of Texas System | Family of pain producing substances and methods to produce novel analgesic drugs |
AU2009319860B2 (en) * | 2008-11-26 | 2016-07-21 | Board Of Regents, The University Of Texas System | A new family of pain producing substances and methods to produce novel analgesic drugs |
US9592301B2 (en) | 2012-09-17 | 2017-03-14 | Board Of Regents Of The University Of Texas System | Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof |
US10100317B2 (en) | 2012-09-17 | 2018-10-16 | Board Of Regents Of The University Of Texas System | Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof |
CN116179488A (en) * | 2023-03-09 | 2023-05-30 | 广东唯泰生物科技有限公司 | In vitro amplification method of peripheral blood natural killer cells |
Also Published As
Publication number | Publication date |
---|---|
AU2000265107A1 (en) | 2002-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10201515B2 (en) | Use of derivatives of polyunsaturated fatty acids as medicaments | |
US5840715A (en) | Dietary regimen of nutritional supplements for relief of symptoms of arthritis | |
US6645948B2 (en) | Nutritional composition for the treatment of connective tissue | |
US4877620A (en) | Ibuprofen-containing medicament | |
JP2925326B2 (en) | Methods for promoting human nitrogen retention | |
JP5667737B2 (en) | Canine osteoarthritis diet formulation | |
KR101075816B1 (en) | Total enteral nutritious composition | |
US6136795A (en) | Dietary regimen of nutritional supplements for relief of symptoms of arthritis | |
US20040162269A1 (en) | Composition and method of treating arthritis | |
JP2001510799A (en) | Therapeutic and dietary compositions comprising essential fatty acids and bioactive disulfides | |
JPH0651626B2 (en) | Composition for treating tissue degenerative inflammatory disease | |
JP2003504333A (en) | Formulations and nutritional compositions containing essential fatty acids and homocysteine lowering agents | |
RU2001110097A (en) | THERAPEUTIC COMPOSITIONS (II) | |
JP2010090140A (en) | Krill and/or marine organism extract for prevention and/or treatment of cardiovascular disease, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport | |
EP0855908B1 (en) | Dietary regimen of nutritional supplements for relief of symptoms of arthritis | |
US20070270376A1 (en) | Combinations of Hyaluronic Acid and Polyunsaturated Fatty Acids | |
EP0734723A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
JPS58208234A (en) | Essential fatty acid-containing medicinal composition | |
DE19818563A1 (en) | Reducing appetite and body weight, especially for treating obesity, by administration of alpha-lipoic acid | |
US6838451B1 (en) | Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases | |
KR100861430B1 (en) | Preparations and Method of Producing the Same | |
WO2002009725A1 (en) | Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases | |
US5541227A (en) | Ibuprofen-containing medicament | |
GB2286528A (en) | Dietary supplement | |
JP5952556B2 (en) | Pressure ulcer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10333295 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |